Disposition of 10000 shares by Struthers Richard Scott of Crinetics Pharmaceuticals at 57.57 subject to Rule 16b-3
| PRRUF Stock | USD 0.20 0.00 0.00% |
Roughly 62% of Immutep's investor base is looking to short. The analysis of overall sentiment of trading Immutep Limited pink sheet suggests that many investors are alarmed at this time. The current market sentiment, together with Immutep's historical and current headlines, can help investors time the market. In addition, many technical investors use Immutep Limited stock news signals to limit their universe of possible portfolio assets.
Immutep pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Immutep daily returns and investor perception about the current price of Immutep Limited as well as its diversification or hedging effects on your existing portfolios.
Immutep |
Filed transaction by Crinetics Pharmaceuticals Director, Officer: President & Ceo. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Immutep Fundamental Analysis
We analyze Immutep's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immutep using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immutep based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Earning
Price To Earning Comparative Analysis
Immutep is currently under evaluation in price to earning category among its peers. Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Immutep Limited Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Immutep pink sheet to make a market-neutral strategy. Peer analysis of Immutep could also be used in its relative valuation, which is a method of valuing Immutep by comparing valuation metrics with similar companies.
Peers
Immutep Related Equities
| IMMX | Immix Biopharma | 5.48 | ||||
| CRNX | Crinetics Pharmaceuticals | 5.21 | ||||
| DSGN | Design Therapeutics | 4.23 | ||||
| APLT | Applied Therapeutics | 2.48 | ||||
| AADI | Aadi Bioscience | 1.67 | ||||
| CYTK | Cytokinetics | 0.30 | ||||
| CGEM | Cullinan Oncology | 0.24 | ||||
| ALVR | Allovir | 0.73 | ||||
| GPCR | Structure Therapeutics | 1.30 | ||||
| CDTX | Cidara Therapeutics | 1.58 | ||||
| VRDN | Viridian Therapeutics | 1.96 | ||||
| ENVB | Enveric Biosciences | 2.47 | ||||
| ZNTL | Zentalis Pharmaceuticals | 3.05 | ||||
| CTMX | CytomX Therapeutics | 3.31 | ||||
| ALXO | Alx Oncology | 3.80 | ||||
| ELEV | Elevation Oncology | 4.00 | ||||
| SANA | Sana Biotechnology | 5.65 | ||||
| ZURA | Zura Bio | 9.71 | ||||
| OLMA | Olema Pharmaceuticals | 12.76 | ||||
| SLN | Silence Therapeutics | 12.84 | ||||
| ADCT | ADC Therapeutics | 36.21 |
Complementary Tools for Immutep Pink Sheet analysis
When running Immutep's price analysis, check to measure Immutep's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immutep is operating at the current time. Most of Immutep's value examination focuses on studying past and present price action to predict the probability of Immutep's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immutep's price. Additionally, you may evaluate how the addition of Immutep to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |